Advertisement
Screener

CYTOKINETICS, INCORPORATED (CYTK) Material Contracts, 2009

CYTOKINETICS, INCORPORATED Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2009-08-06: Form 10-Q; Exhibit 10.74; Description CONSENT AND AMENDMENT NO. 2 TO MASTER SECURITY.
  • 2009-08-06: Form 10-Q; Exhibit 10.73; Description Amendment No. 1, effective January 1, 2005, to Master Security Agreement by and between the Company and General Electric Capital Corporation..
  • 2009-08-06: Form 10-Q; Exhibit 10.71; Description CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED.
  • 2009-08-06: Form 10-Q; Exhibit 10.2; Description 2004 Equity Incentive Plan, as amended..
FiledFormExhibitDescription
2009-08-0610-Q10.74CONSENT AND AMENDMENT NO. 2 TO MASTER SECURITY
2009-08-0610-Q10.73Amendment No. 1, effective January 1, 2005, to Master Security Agreement by and between the Company and General Electric Capital Corporation.
2009-08-0610-Q10.71CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
2009-08-0610-Q10.22004 Equity Incentive Plan, as amended.
2009-05-198-K10.70Form of Warrant, dated May 18, 2009, between the Company and the investor signatories thereto.
2009-05-198-K10.69Form of Subscription Agreement, dated May 18, 2009, between the Company and the investor signatories thereto.
2009-03-1210-K10.68Re: Amendment No. 1 to Amended and Restated Executive Employment Agreement
2009-03-1210-K10.67CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
2009-03-1210-K10.66Credit Line Account Application and Agreement for Organizations and Businesses For Internal Use
2009-03-1210-K10.65CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
2009-03-1210-K10.64UBS Financial Services Inc.
2009-03-1210-K10.63Re: Amendment Number Two to Collaboration and Option Agreement
2009-03-1210-K10.62Re: Amendment No. 1 to Collaboration and Option Agreement
2009-03-1210-K10.55CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Alkermes plc. (ALKS)$6.844B132.74